Printer Friendly
The Free Library
19,604,530 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BIO Encourages Its Members to Adopt Code of Conduct to Govern Interactions With Healthcare Professionals.


Members Should Maintain "Highest Standards" for Ethical Business Practices Related to Interactions

WASHINGTON -- The Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
  • BIO Website
 (BIO) announced today a new policy statement regarding interactions between BIO's healthcare-related member companies and healthcare professionals. The policy, approved last week by BIO's Health Section Governing Board Noun 1. governing board - a board that manages the affairs of an institution
board - a committee having supervisory powers; "the board has seven members"
, encourages each of BIO's members involved in the marketing of biologics or other pharmaceuticals to United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area.  healthcare professionals to adopt "a transparent and rigorous code of conduct," which also "ensures compliance with all applicable local, state and federal laws and regulations."

In its statement, BIO reiterated that the organization and its member companies "remain dedicated to the improvement of patient care and the advancement of medical science. In pursuing this mission, we recognize that adherence to strict ethical standards and compliance with applicable laws is critical to our industry's ability to continue our collaboration with healthcare professionals and maintain the trust of our patients."

BIO also announced its support for the principles contained in the "Code on Interactions with Healthcare Professionals" adopted by the Pharmaceutical Research and Manufacturers of America Pharmaceutical Research and Manufacturers of America (PhRMA) is an industry trade group representing the pharmaceutical research and biotechnology companies in the United States.  (PhRMA) last year. In its new policy statement, BIO encourages its members to adopt a code of conduct such as the PhRMA code.

"The novel and state-of-the-art therapies that are the object of the research of our member companies demand that these companies help provide continuing education continuing education: see adult education.
continuing education
 or adult education

Any form of learning provided for adults. In the U.S. the University of Wisconsin was the first academic institution to offer such programs (1904).
 to healthcare professionals. These educational interactions help healthcare professionals make informed decisions in consultation with their patients based on the most up-to-date information," stated BIO President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  Jim Greenwood Greenwood.

1 City (1990 pop. 26,265), Johnson co., central Ind.; settled 1822, inc. as a city 1960. A residential suburb of Indianapolis, Greenwood is in a retail shopping area. Manufactures include motor vehicle parts and metal products.
. "These interactions must continue to be governed by the highest ethical standards so that we maintain our bond of trust with patients and healthcare providers."

"Our policy statement recognizes the difficulty in crafting a 'one-size-fits-all' code of conduct for our diverse membership," added BIO Board and Health Section Governing Board Chair Dr. Joshua Boger. "At the same time, it reinforces the need for BIO member companies to continue to adhere to adhere to
verb 1. follow, keep, maintain, respect, observe, be true, fulfil, obey, heed, keep to, abide by, be loyal, mind, be constant, be faithful

2.
 the highest ethical standards, specifically in their marketing and healthcare professional education practices, and to be transparent with the public as to their activities in this regard."

BIO's full policy statement reads:

BIO statement regarding PhRMA's revised Code on Interactions with Healthcare Professionals (the Code)

BIO and our member companies remain dedicated to the improvement of patient care and the advancement of medical science. In pursuing this mission, we recognize that adherence to strict ethical standards and compliance with applicable laws is critical to our industry's ability to continue our collaboration with healthcare professionals and maintain the trust of our patients. For these reasons, BIO supports the principles in PhRMA's Code governing interactions with healthcare professionals, and will continue to encourage its members to maintain the highest standards for ethical business practices and socially responsible industry conduct related to company interactions with healthcare professionals.

Specifically, BIO encourages each of its member companies that are involved in the marketing of biologics or other pharmaceuticals to United States healthcare professionals to adopt a transparent and rigorous code of conduct, such as the PhRMA Code, tailored as appropriate to its own particular circumstances and which also ensures compliance with all applicable local, state, and federal laws and regulations. BIO members that wish to sign on to the PhRMA Code may do so, even if they are not PhRMA members.

About BIO

BIO represents more than 1,200 biotechnology companies Top 100 Biotechnology Companies
The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies.
, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology Environmental biotechnology is when biotechnology is applied to and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation.  products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Upcoming BIO Events

BIO-Europe Spring March 16-18, 2009 Milan, Italy

BIO IP Counsels' Committee Conference March 25-27, 2009 Phoenix, AZ

BIO National Venture Conference March 31-April 1,2009 Boston, MA

BIO Windhover wind·hov·er  
n. Chiefly British
A kestrel.
 2009 April 13-15, 2009 New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
, New York

BIO-LES Business Development Basics Course May 15-17, 2009 Atlanta, GA

BIO-LES Advanced Business Development Course May 15-17, 2009 Atlanta, GA

BIO Executive Presentation Workshop May 17, 2009 Atlanta, GA

2009 BIO International Convention May 18-21, 2009 Atlanta, GA

BioEquity Europe June 9-10, 2009 Munich, Germany

World Congress on Industrial Biotechnology The references in this article would be clearer with a different and/or consistent style of citation, footnoting or external linking.
Industrial biotechnology (known mainly in Europe as white biotechnology
 & Bioprocessing July 19-22, 2009 Montreal, Quebec, Canada
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 19, 2009
Words:720
Previous Article:Tasty Baking Company to Webcast Fourth Quarter 2008 Financial Results.
Next Article:Fitch Downgrades 14 B-Piece CRE CDOs on Underlying Portfolio Concentration Risk.
Topics:

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles